Panbela Therapeutics (STU:X70) Tariff Resilience Score: 0/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:X70 Panbela Therapeutics Inc STU:X70
29 GF Score
Price €119.40
View Full Analysis

What is Panbela Therapeutics Tariff Resilience Score?

Panbela Therapeutics has the Tariff Resilience Score of 0, which implies that the company might have .

Panbela Therapeutics has PBLA's pharmaceutical development involves international supply chains, exposing it to tariff risks. However, its focus on niche markets and potential for alternative suppliers offer some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Panbela Therapeutics might have .


Panbela Therapeutics  (STU:X70) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Panbela Therapeutics Tariff Resilience Score Related Terms

STU:X70
29GF Score
Panbela Therapeutics Inc STU:X70
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panbela Therapeutics Business Description

Address 712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
29GF Score

Get the complete analysis for STU:X70

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€119.40
Price